menu

Loading...

CING Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

6.590

Open

6.020

VWAP

6.36

Vol

137.19K

Mkt Cap

46.69M

Low

5.980

Amount

872.55K

EV/EBITDA(TTM)

--

Total Shares

7.45M

EV

45.51M

EV/OCF(TTM)

--

P/S(TTM)

--

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Show More

Events Timeline

(ET)

2026-01-12

17:30:00

Cingulate Files $200M Mixed Securities Shelf

2025-11-13 (ET)

2025-11-13

08:11:32

Cingulate Announces Q3 Net Loss of $7.3 Million Compared to $4.1 Million Last Year

2025-11-10 (ET)

2025-11-10

08:23:13

Cingulate Appoints Downey as Chief Commercial Officer to Oversee CTx-1301 Launch Preparation

2025-10-28 (ET)

2025-10-28

08:21:28

Cingulate Reveals Phase 3 Results for CTx-1301, Achieves Primary Endpoint

2025-10-14 (ET)

2025-10-14

08:03:04

Cingulate Reports FDA Has Accepted NDA for CTx-1301 for Review

2025-09-17 (ET)

2025-09-17

08:47:51

Cingulate Forms Exclusive Manufacturing Alliance with Bend Bio Sciences

2025-08-19 (ET)

2025-08-19

08:47:23

Cingulate Announces Q2 Net Loss of $4.8 Million Compared to $3.2 Million Last Year

News

NASDAQ.COM

01-23NASDAQ.COM

Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading

Benzinga

2025-11-19Benzinga

Roth Capital Reaffirms Buy Rating on Cingulate, Reduces Price Target to $16

NASDAQ.COM

2025-10-24NASDAQ.COM

INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading

Newsfilter

2025-10-23Newsfilter

Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting

Benzinga

2025-10-15Benzinga

Roth Capital Reaffirms Buy Rating on Cingulate, Increases Price Target to $17

Newsfilter

2025-09-17Newsfilter

Cingulate Forms Exclusive Manufacturing Alliance with Bend Bio Sciences for Upcoming ADHD Treatment Commercialization

3 Analyst Rating

Wall Street analysts forecast CING stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

27.33

High

58.00

Current: 0.000

Low

8.00

Averages

27.33

High

58.00

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$17 -> $16

AI Analysis

2025-11-18

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$17 -> $16

AI Analysis

2025-11-18

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.

Roth Capital

NULL

to

Buy

upgrade

$10 -> $17

2025-10-14

Reason

Roth Capital

Price Target

$10 -> $17

2025-10-14

upgrade

NULL

to

Buy

Reason

Roth Capital raised the firm's price target on Cingulate to $17 from $10 and keeps a Buy rating on the shares. The FDA's acceptance of Cingulate's NDA package suggests that the agency is likely comfortable with the safety-efficacy characteristics of CTx-1301 in ADHD patients, the analyst tells investors in a research note. The lack of Ad Comm, a PDUFA date that is at least 2 months ahead of Roth's expectations, a potential broad label to all ADHD patients, and importantly, the stellar approval record of all ADHD stimulants, are all good reasons to buy Cingulate stock, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CING

Unlock Now

Valuation Metrics

The current forward P/E ratio for Cingulate Inc (CING.O) is -1.41, compared to its 5-year average forward P/E of -8.49. For a more detailed relative valuation and DCF analysis to assess Cingulate Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-8.49

Current PE

-1.41

Overvalued PE

51.94

Undervalued PE

-68.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

15.37

Current PS

177.54

Overvalued PS

58.88

Undervalued PS

-28.14

Financials

AI Analysis

Annual

Quarterly

Whales Holding CING

Trading Trends

People Also Watch

Frequently Asked Questions

What is Cingulate Inc (CING) stock price today?

The current price of CING is 6.51 USD — it has increased 3.83

What is Cingulate Inc (CING)'s business?

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

What is the price predicton of CING Stock?

Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is27.33 USD with a low forecast of 8.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cingulate Inc (CING)'s revenue for the last quarter?

Cingulate Inc revenue for the last quarter amounts to -6.00M USD, increased 82.68

What is Cingulate Inc (CING)'s earnings per share (EPS) for the last quarter?

Cingulate Inc. EPS for the last quarter amounts to -4244354.00 USD, increased 9.29

How many employees does Cingulate Inc (CING). have?

Cingulate Inc (CING) has 13 emplpoyees as of March 02 2026.

What is Cingulate Inc (CING) market cap?

Today CING has the market capitalization of 46.69M USD.